Kurs
-0,28%
Likviditet
0,11 MSEK
Kalender
Tid* | ||
2025-03-13 | 13:30 | Kvartalsrapport 2025-Q3 |
2025-01-08 | N/A | Extra Bolagsstämma 2025 |
2024-11-28 | - | Kvartalsrapport 2025-Q2 |
2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2024-09-16 | - | Kvartalsrapport 2025-Q1 |
2024-06-26 | - | Bokslutskommuniké 2024 |
2024-03-27 | - | Kvartalsrapport 2024-Q3 |
2023-12-21 | - | Kvartalsrapport 2024-Q2 |
2023-11-15 | - | Extra Bolagsstämma 2024 |
2023-10-27 | - | Årsstämma |
2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2023-09-20 | - | Kvartalsrapport 2024-Q1 |
2023-06-23 | - | Bokslutskommuniké 2023 |
2023-05-09 | - | Extra Bolagsstämma 2023 |
2023-03-28 | - | Kvartalsrapport 2023-Q3 |
2022-12-21 | - | Kvartalsrapport 2023-Q2 |
2022-10-31 | - | Årsstämma |
2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2022-09-29 | - | Kvartalsrapport 2023-Q1 |
2022-06-29 | - | Bokslutskommuniké 2022 |
2022-03-21 | - | Kvartalsrapport 2022-Q3 |
2022-03-15 | - | Extra Bolagsstämma 2022 |
2021-12-29 | - | Kvartalsrapport 2022-Q2 |
2021-10-20 | - | Extra Bolagsstämma 2021 |
2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2021-09-29 | - | Kvartalsrapport 2022-Q1 |
2021-06-24 | - | Bokslutskommuniké 2021 |
2021-03-16 | - | Kvartalsrapport 2021-Q3 |
2020-12-14 | - | Kvartalsrapport 2021-Q2 |
2020-10-20 | - | Årsstämma |
2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2020-09-28 | - | Kvartalsrapport 2021-Q1 |
2020-06-25 | - | Bokslutskommuniké 2020 |
2020-03-12 | - | Kvartalsrapport 2020-Q3 |
2019-12-17 | - | Kvartalsrapport 2020-Q2 |
2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2019-10-15 | - | Årsstämma |
2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2018-09-26 | - | Årsstämma |
2018-06-18 | - | Extra Bolagsstämma 2019 |
2018-06-12 | - | Bokslutskommuniké 2018 |
2018-03-12 | - | Kvartalsrapport 2018-Q3 |
2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2017-09-25 | - | Årsstämma |
2017-09-11 | - | Kvartalsrapport 2018-Q1 |
2017-06-19 | - | Bokslutskommuniké 2017 |
2017-03-13 | - | Kvartalsrapport 2017-Q3 |
2017-01-01 | - | Extra Bolagsstämma 2018 |
2016-11-30 | - | Kvartalsrapport 2017-Q2 |
2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2016-09-05 | - | Årsstämma |
2016-09-05 | - | Kvartalsrapport 2017-Q1 |
2016-06-13 | - | Bokslutskommuniké 2016 |
2016-02-22 | - | Kvartalsrapport 2016-Q3 |
2016-02-16 | - | Extra Bolagsstämma 2017 |
2015-11-30 | - | Kvartalsrapport 2016-Q2 |
2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2015-09-07 | - | Årsstämma |
2015-09-07 | - | Kvartalsrapport 2016-Q1 |
2015-06-16 | - | Bokslutskommuniké 2015 |
2015-03-16 | - | Kvartalsrapport 2015-Q3 |
2014-12-01 | - | Kvartalsrapport 2015-Q2 |
2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2014-10-06 | - | Årsstämma |
2014-10-06 | - | Kvartalsrapport 2015-Q1 |
2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
Phase Holographic Imaging (PHI) is pleased to announce a strategic activity schedule for spring 2024, during which PHI will participate in select industry webinars and events. PHI's initiatives aim to foster collaboration and reinforce PHI's role as a thought leader for creating standardized cell quality control in regenerative medicine by connecting with leading professionals, researchers, and innovators to support knowledge exchange and partnership opportunities.
As previously communicated, PHI has joined the International Alliance for Regenerative Medicine (ARM) (https://alliancerm.org/), an organization that advocates for cell and genetic therapies and is represented by 475 members in 25 countries. The organization promotes collaboration between scientists, healthcare professionals, and industry to advance the development of advanced therapy medicinal products (ATMPs) and organizes several international conferences throughout the year.
[image]
Cell & Gene Meeting on the Mediterranean (Rome, April 9-11)
PHI will begin its spring activities with attendance at ARM's leading conference, "Cell & Gene Meeting on the Mediterranean (https://meetingonthemed.com/)", in Rome from April 9-11. This conference serves as an important forum for the European cell and gene therapy community, exploring a broad range of commercialization-related topics. Participants will discuss market entry strategies, regulatory considerations, manufacturing issues, and financial planning in the industry. Representing PHI, CSO Kersti Alm will introduce PHI and highlight the advantages of PHI's innovative Quantitative Phase Imaging (QPI) technology, discussing its applications for advanced cell quality control in cell therapy manufacturing.
[image]
RegMIC annual meeting (Charlotte, NC, May 15)
On May 15, PHI will attend the RegMIC annual meeting (https://remdo.org/2024-regmic-annual-meeting-registration/) in Charlotte, North Carolina. The Regenerative Manufacturing Innovation Consortium (RegMIC) is a non-profit organization committed to accelerating the development and commercialization of regenerative medicine therapies. The meeting will convene industry leaders, researchers, and innovators to explore the latest advancements and opportunities in regenerative medicine. As a RegMIC member, a PHI delegation will be there to advocate for QPI technology in standardized cell quality control measurements and engage with the regenerative medicine community to drive collaborations and commercialization activities.
Lisa Bodily
E-mail: ir@phiab.com (ir@phiab.se)
Web: www.phiab.com - Live cell imaging & analysis